highly active antiretroviral therapy

Summary

Summary: Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.

Top Publications

  1. pmc Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Lancet 376:532-9. 2010
  2. pmc Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 105:3879-84. 2008
  3. ncbi Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
    Janet D Siliciano
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205 USA
    Nat Med 9:727-8. 2003
  4. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
  5. ncbi Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study
    Frank J Palella
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 43:27-34. 2006
  6. ncbi Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa
    A P Hardon
    University of Amsterdam, Amsterdam School for Social Science Research, Amsterdam, The Netherlands
    AIDS Care 19:658-65. 2007
  7. ncbi Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
    Matthias Egger
    Department of Social and Preventive Medicine, University of Bern, CH 3012 Bern, Switzerland
    Lancet 360:119-29. 2002
  8. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
  9. ncbi T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Infect Dis 187:1534-43. 2003
  10. ncbi Survival of persons with and without HIV infection in Denmark, 1995-2005
    Nicolai Lohse
    Department of Infectious Diseases, Odense University Hospital and University of Southern Denmark, Odense, Denmark
    Ann Intern Med 146:87-95. 2007

Detail Information

Publications281 found, 100 shown here

  1. pmc Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Lancet 376:532-9. 2010
    Results of cohort studies and mathematical models have suggested that increased coverage with highly active antiretroviral therapy (HAART) could reduce HIV transmission...
  2. pmc Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 105:3879-84. 2008
    ..These data suggest that low-level persistent viremia appears to arise from at least two cell compartments, one in which viral production decays over time and a second in which viral production remains stable for at least 7 years...
  3. ncbi Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
    Janet D Siliciano
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205 USA
    Nat Med 9:727-8. 2003
    Latent HIV-1 persists in resting memory CD4+ T cells, even in patients receiving highly active antiretroviral therapy (HAART)...
  4. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
    Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1 mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe.
  5. ncbi Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study
    Frank J Palella
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 43:27-34. 2006
    AIDS-related death and disease rates have declined in the highly active antiretroviral therapy (HAART) era and remain low; however, current causes of death in HAART-treated patients remain ill defined.
  6. ncbi Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa
    A P Hardon
    University of Amsterdam, Amsterdam School for Social Science Research, Amsterdam, The Netherlands
    AIDS Care 19:658-65. 2007
    ....
  7. ncbi Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
    Matthias Egger
    Department of Social and Preventive Medicine, University of Bern, CH 3012 Bern, Switzerland
    Lancet 360:119-29. 2002
    ..studies to allow estimation of the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral therapy (HAART)...
  8. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
    ..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
  9. ncbi T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Infect Dis 187:1534-43. 2003
    ..Interventions that directly target T cell activation or the determinants of activation may prove to be useful adjuvants to antiretroviral therapy...
  10. ncbi Survival of persons with and without HIV infection in Denmark, 1995-2005
    Nicolai Lohse
    Department of Infectious Diseases, Odense University Hospital and University of Southern Denmark, Odense, Denmark
    Ann Intern Med 146:87-95. 2007
    ..The expected survival of HIV-infected patients is of major public health interest...
  11. ncbi Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
    Paula Braitstein
    Lancet 367:817-24. 2006
    b>Highly active antiretroviral therapy (HAART) is being scaled up in developing countries...
  12. ncbi Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals
    Stephen D Lawn
    Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Lancet Infect Dis 5:361-73. 2005
    ..We also discuss the problem of IRD associated with mycobacterial diseases in developing countries where tuberculosis prevalence is high and access to HAART is currently expanding...
  13. pmc Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review
    Sydney Rosen
    Center for International Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 4:e298. 2007
    ..In this paper we present a systematic review of patient retention in ART programs in sub-Saharan Africa...
  14. ncbi Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City
    Judith E Sackoff
    HIV Epidemiology Program, Bureau of HIV AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, New York, New York 10013, USA
    Ann Intern Med 145:397-406. 2006
    Monitoring the full spectrum of causes of death among persons with AIDS is increasingly important as survival improves because of highly active antiretroviral therapy.
  15. ncbi Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    JAMA 296:679-90. 2006
    ..Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa...
  16. pmc Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS
    Thomas W North
    Center for Comparative Medicine, Department of Veterinary Molecular Biosciences, University of California, Davis, CA 95616, USA
    J Virol 84:2913-22. 2010
    b>Highly active antiretroviral therapy (HAART) enables long-term suppression of plasma HIV-1 loads in infected persons, but low-level virus persists and rebounds following cessation of therapy...
  17. pmc Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes
    Yefei Han
    Department of Medicine, Ross 1049, School of Medicine, Johns Hopkins University, 720 Rutland Ave, Baltimore, MD 21205, USA
    J Virol 78:6122-33. 2004
    ..In individuals showing suppression of viremia during highly active antiretroviral therapy (HAART), resting CD4+ T-cell populations do not produce virus without cellular activation...
  18. ncbi The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, University of British Columbia, Vancouver, Canada
    Lancet 368:531-6. 2006
  19. pmc HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
    Nicolas Chomont
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal Saint Luc, Montreal, Quebec, Canada
    Nat Med 15:893-900. 2009
    HIV persists in a reservoir of latently infected CD4(+) T cells in individuals treated with highly active antiretroviral therapy (HAART)...
  20. pmc IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART
    Feng Xiang Wang
    Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Clin Invest 115:128-37. 2005
    The persistence of HIV-1 in virally suppressed infected individuals on highly active antiretroviral therapy (HAART) remains a major therapeutic problem...
  21. pmc Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
    J B Dinoso
    Departmentsof Medicine and Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 106:9403-8. 2009
    ..Our results suggest that residual viremia is not the product of ongoing, complete cycles of viral replication, but rather of virus output from stable reservoirs of infection...
  22. ncbi Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
    Gary M Clifford
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Natl Cancer Inst 97:425-32. 2005
    ..virus (HIV) have an increased risk for several cancers, but the influences of behavioral risk factors, such as smoking and intravenous drug use, and highly active antiretroviral therapy (HAART) on cancer risk are not clear.
  23. ncbi Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART
    J Kulkosky
    Dorrance H Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Blood 98:3006-15. 2001
    ..whether this compound could serve as an inductive adjuvant therapy for patients treated with highly active antiretroviral therapy (HAART)...
  24. ncbi Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes
    Jeffrey S A Stringer
    Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, USA
    JAMA 296:782-93. 2006
    ..The Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians...
  25. ncbi Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras
    Nancy F Crum
    Infectious Diseases Division, Clinical Investigation Department, Naval Medical Center San Diego, San Diego, CA 92134 1005, USA
    J Acquir Immune Defic Syndr 41:194-200. 2006
    ..Comparisons of death-related variables during the 3 eras were performed...
  26. pmc The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, 608 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
    J Acquir Immune Defic Syndr 50:529-36. 2009
    To characterize the impact of longitudinal adherence on survival in drug-naive individuals starting currently recommended highly active antiretroviral therapy (HAART) regimens.
  27. ncbi Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration
    Paula Braitstein
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    J Womens Health (Larchmt) 17:47-55. 2008
    ....
  28. ncbi Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort
    Deborah Konopnicki
    Division of Infectious Diseases, Saint Pierre University Hospital, Brussels, Belgium
    AIDS 19:593-601. 2005
    ..Whether hepatitis B (HBV) coinfection affects outcome in HIV-1-infected patients remains unclear...
  29. ncbi Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, British Columbia, Canada
    J Infect Dis 198:51-8. 2008
    We explore the temporal and regimen-specific changes of HIV-1 drug resistance in a large cohort of antiretroviral-naive individuals starting highly active antiretroviral therapy (HAART).
  30. ncbi Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy
    Christine M Posavad
    Department of Laboratory Medicine, University of Washington, and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Infect Dis 190:693-6. 2004
    The effect of highly active antiretroviral therapy (HAART) on control of herpes simplex virus (HSV) in human immunodeficiency virus (HIV) type 1-infected subjects is not known...
  31. ncbi Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003
    Eric C Seaberg
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    AIDS 19:953-60. 2005
    UO1-AI-35041: To examine the impact of HIV infection and highly active antiretroviral therapy on systolic and diastolic hypertension.
  32. ncbi The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study
    Perrine Roux
    INSERM U912 SE4S, Marseille, France
    Addiction 103:1828-36. 2008
    To date, no data exist assessing the impact of either methadone or buprenorphine on adherence to highly active antiretroviral therapy (HAART) in the long term...
  33. ncbi Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa
    Kathryn Stinson
    Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    Trop Med Int Health 15:825-32. 2010
    To investigate highly active antiretroviral therapy (HAART) initiation among pregnant women and the optimum model of service delivery for integrating HAART services into antenatal care.
  34. pmc Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project
    Helen Ding
    Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Arch Pediatr Adolesc Med 163:1100-5. 2009
    To examine the prevalence and biopsychosocial predictors of suboptimal virologic response to highly active antiretroviral therapy (HAART) among human immunodeficiency virus-infected adolescents.
  35. pmc Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
    Ginger Lehrman
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 753901, USA
    Lancet 366:549-55. 2005
    ..Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells...
  36. ncbi Trends in cancer risk among people with AIDS in the United States 1980-2002
    Eric A Engels
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852, USA
    AIDS 20:1645-54. 2006
    ..People with AIDS have heightened cancer risk from immunosuppression. HAART has been available since 1996 and has reduced AIDS-related mortality, but there are few large-scale studies on cancer trends...
  37. doi Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008
  38. pmc Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  39. ncbi Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    N Engl J Med 352:570-85. 2005
    The costs, benefits, and cost-effectiveness of screening for human immunodeficiency virus (HIV) in health care settings during the era of highly active antiretroviral therapy (HAART) have not been determined.
  40. ncbi Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    AIDS 19:2109-16. 2005
    ..To determine the long-term incidence of tuberculosis (TB) and associated risk factors among individuals receiving HAART in South Africa...
  41. ncbi Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study
    Rainer Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH 809a Zurich, Switzerland
    Arch Intern Med 166:1632-41. 2006
    ..An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases...
  42. ncbi Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Cape Town, South Africa
    AIDS 19:2141-8. 2005
    ..To determine rates, risk factors and causes of death among patients accessing a community-based antiretroviral treatment (ART) programme both prior to and following initiation of treatment...
  43. ncbi Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy
    Giulia Marchetti
    Department of Medicine, Surgery and Dentistry, Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    AIDS 22:2035-8. 2008
    Patients with inefficient CD4+ T-cell recovery on virogically suppressive highly active antiretroviral therapy constitute a major clinical hurdle given the threat of HIV/AIDS disease progression...
  44. ncbi Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy
    Anna Suy
    Obstetric and Gynecological Service, Hospital Clinic of the Institute of Biomedical Investigations, August Pi i Sunyer Hospital, University of Barcelona, Barcelona, Spain
    AIDS 20:59-66. 2006
    ..Pre-eclampsia and/or fetal death have increased sharply in HIV-infected pregnant women receiving HAART...
  45. ncbi Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda
    Cheryl A Liechty
    Centers for Disease Control and Prevention CDC Uganda, Entebbe, Uganda
    Trop Med Int Health 12:929-35. 2007
    ..Cryptococcal meningitis is a leading cause of HIV-related mortality in Africa, but current guidelines do not advocate CRAG testing as a screening tool...
  46. ncbi Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials
    Marijn de Bruin
    Department of Work and Social Psychology, Maastricht University, The Netherlands
    Arch Intern Med 170:240-50. 2010
    ..Systematic reviews can identify practical and effective interventions. Meta-analyses that control for variability in standard care provided to control groups may produce more accurate estimates of intervention effects...
  47. pmc Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    PLoS Med 3:e438. 2006
    Adherence to highly active antiretroviral therapy (HAART) medication is the greatest patient-enabled predictor of treatment success and mortality for those who have access to drugs...
  48. ncbi Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review
    Nicole Crepaz
    Division of HIV AIDS Prevention, US Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 292:224-36. 2004
    Evidence suggests that since highly active antiretroviral therapy (HAART) became available, the prevalence of unprotected sex and the incidence of sexually transmitted infections (STIs) have increased.
  49. pmc Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda
    Putu Duff
    School of Public Health, University of Alberta, Canada
    J Int AIDS Soc 13:37. 2010
    The aim of this study was to describe barriers to accessing and accepting highly active antiretroviral therapy (HAART) by HIV-positive mothers in the Ugandan Kabarole District's Programme for the Prevention of Mother to Child Transmission-..
  50. pmc Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials
    Jane M Simoni
    Department of Psychology, University of Washington, Seattle, Washington 98195 1525, USA
    J Acquir Immune Defic Syndr 43:S23-35. 2006
    Adherence to highly active antiretroviral therapy (HAART) is generally suboptimal, limiting the effectiveness of HAART...
  51. pmc Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa
    Risa M Hoffman
    David Geffen School of Medicine at UCLA, Division of Infectious Diseases and Center for Clinical AIDS Research and Education, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 54:35-41. 2010
    Limited information exists about effects of different highly active antiretroviral therapy (HAART) regimens and duration of regimens on mother-to-child transmission (MTCT) of HIV among women in Africa who start treatment for advanced ..
  52. ncbi Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa
    Raoul Moh
    Trivacan ANRS 1269 study group, Abidjan, France
    AIDS 21:2483-91. 2007
    ..To estimate the incidence and risk factors of mortality and severe morbidity during the first months following antiretroviral therapy (ART) initiation in West African adults...
  53. ncbi Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection
    Lin Shen
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Allergy Clin Immunol 122:22-8. 2008
    Although highly active antiretroviral therapy (HAART) can reduce HIV-1 viremia to levels that are below the limit of detection of clinical assays, the virus persists in reservoirs, and trace levels of free virions can be found in the ..
  54. pmc Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype
    Deirdre D Scripture-Adams
    Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Virol 76:13077-82. 2002
    ..Thus, IL-7 is a viable candidate to activate expression of latent HIV and may facilitate immune clearance of latently infected cells...
  55. ncbi Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review
    Emanuele Nicastri
    National Institute for Infectious Diseases, IRCCS Lazzaro Spallanzani, Rome, Italy
    J Antimicrob Chemother 60:724-32. 2007
    Since the introduction of highly active antiretroviral therapy (HAART), morbidity and mortality rates have sharply decreased among HIV-infected patients...
  56. ncbi Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis
    Ravindra K Gupta
    UCL MRC Centre for Medical Molecular Virology, University College London Medical School, London, UK
    Lancet Infect Dis 9:409-17. 2009
    ..This Review highlights the need for cheap point-of-care viral-load tests to identify early viral failures and limit the emergence of resistance...
  57. ncbi Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients
    Paola Cicconi
    Department of Infectious Diseases and Tropical Medicine, Università degli Strudi di Milano H S Paolo, Milan, Italy
    HIV Med 11:104-13. 2010
    The aim of the study was to determine whether the incidence of first-line treatment discontinuations and their causes changed according to the time of starting highly active antiretroviral therapy (HAART) in an Italian cohort.
  58. ncbi Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia
    Bart Janssens
    Medecins Sans Frontieres, Phnom Penh, Cambodia
    Pediatrics 120:e1134-40. 2007
    Increasing access to highly active antiretroviral therapy to reach all those in need in developing countries (scale up) is slowly expanding to HIV-positive children, but documented experience remains limited...
  59. ncbi Impact of HIV infection and HAART on serum lipids in men
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 289:2978-82. 2003
    ..have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values.
  60. ncbi Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study
    Katie B Anderson
    Rollins School of Public Health at Emory University, Emory University, Atlanta, Georgia, USA
    Clin Infect Dis 39:1507-13. 2004
    ..We compared survival among patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) with that among patients infected solely with HIV...
  61. pmc Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy
    Andrew Kambugu
    Infectious Disease Institute, Makerere University, Kampala Uganda
    Clin Infect Dis 46:1694-701. 2008
    ..Cryptococcal meningitis (CM) is the proximate cause of death in 20%-30% of persons with acquired immunodeficiency syndrome in Africa...
  62. ncbi Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, British Columbia, Canada
    J Infect Dis 198:59-67. 2008
    ..using a multiple source of infection framework to assess the potential effect of the expansion of highly active antiretroviral therapy (HAART) coverage among those in medical need on the number of individuals testing newly positive ..
  63. pmc Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa
    Vincent C Marconi
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02139, USA
    Clin Infect Dis 46:1589-97. 2008
    ..The prevalence of resistance was assessed among patients from KwaZulu Natal, South Africa, following failure of their first highly active antiretroviral therapy (HAART) regimen.
  64. ncbi The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials
    Sharon Mannheimer
    Harlem Hospital and Columbia University, New York, NY, USA
    Clin Infect Dis 34:1115-21. 2002
    ..001). Nonwhite race was associated with poorer adherence (P<.001), and older age was associated with better adherence (P<.001)...
  65. pmc Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy
    G Paolo Rizzardi
    Laboratory of AIDS Immunopathogenesis, Division of Immunology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    J Clin Invest 109:681-8. 2002
    ..tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection...
  66. ncbi CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression
    Richard D Moore
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Infect Dis 44:441-6. 2007
    Sustained suppression of the human immunodeficiency virus (HIV) type 1 RNA load with the use of highly active antiretroviral therapy (HAART) results in immunologic improvement, but it is not clear whether the CD4(+) cell count increases ..
  67. ncbi Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy
    Gregory M Lucas
    Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Epidemiol 163:412-20. 2006
    ..2, 2.8). Active drug use is temporally linked to HIV disease progression and mortality. Effectively targeting and treating active substance abuse in HIV treatment settings may provide a mechanism to improve clinical outcomes...
  68. pmc Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy
    Moraima Guadalupe
    Department of Medical Microbiology and Immunology, University of California, Davis, California 95616, USA
    J Virol 77:11708-17. 2003
    ..during both primary and chronic stages of HIV-1 infection, prior to and following the initiation of highly active antiretroviral therapy (HAART) to determine the onset of CD4(+) T-cell depletion and the effect of HAART on the ..
  69. pmc Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
    Travis C Porco
    San Francisco Department of Public Health, Community Health and Epidemiology Section, San Francisco, CA, USA
    AIDS 18:81-8. 2004
    ..We estimated the degree to which the probability of HIV infection from an infected partner (the infectivity) declined following the introduction of highly active antiretroviral therapy (HAART) in San Francisco.
  70. ncbi Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy
    C T Fang
    Department of Internal Medicine, National Taiwan University Hospital, No 7 Chung San South Road, Taipei, Taiwan
    QJM 100:97-105. 2007
    Limited data are available on the life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy (HAART).
  71. ncbi Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials
    Ravindra Gupta
    Division of Infection and Immunity, University College London, London, United Kingdom
    Clin Infect Dis 47:712-22. 2008
    ..Resistance to antiretroviral combination therapy is associated with increased mortality. Understanding the relative risks of emerging resistance to first-line therapy is of importance for both resource-rich and resource-poor settings...
  72. pmc Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification
    Maya L Petersen
    Division of Biostatistics, Berkeley School of Public Health, Berkeley, California 94720, USA
    AIDS 22:2097-106. 2008
    ..These recommendations have not been tested in observational studies or large randomized trials. We evaluated the consequences of delayed modification following virologic failure...
  73. pmc A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy
    Jason B Dinoso
    Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Virol 83:9247-57. 2009
    The treatment of human immunodeficiency virus type 1 (HIV-1) infection with highly active antiretroviral therapy (HAART), a combination of three or more antiretroviral drugs, suppresses viremia below the clinical limit of detection (50 ..
  74. pmc Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC
    CMAJ 169:656-61. 2003
    The benefits of highly active antiretroviral therapy (HAART) for the treatment of HIV infection are well documented, but concerns regarding access and adherence to HAART are growing...
  75. ncbi Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature
    Adriana Ammassari
    Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, Roma, Italy
    J Acquir Immune Defic Syndr 31:S123-7. 2002
    ..This review summarizes the results of 20 studies investigating the issue of barriers to optimal highly active antiretroviral therapy (HAART) adherence. Only a few determinants were consistently associated with nonadherence...
  76. pmc Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy
    Justin R Bailey
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Virol 80:4758-70. 2006
    ..patients with viral loads of <50 copies/ml of plasma, including patients on effective highly active antiretroviral therapy (HAART) and elite suppressors, who control HIV-1 replication without antiretroviral therapy...
  77. ncbi Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
    Gillian L Dean
    St Thomas Hospital, London, UK
    AIDS 16:75-83. 2002
    To assess the risks and benefits of administering highly active antiretroviral therapy (HAART) during the treatment of tuberculosis (TB) in HIV-infected patients.
  78. ncbi Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients
    Magid Herida
    Institut National de la Santé et de la Recherche Médicale Equipe Mixte 0214, 56 Boulevard Vincent Auriol, BP 335, 75625 Paris Cedex 13, France
    J Clin Oncol 21:3447-53. 2003
    ..of non-AIDS-defining cancers (NADC) in HIV-infected patients before (P1) and during (P2) the use of highly active antiretroviral therapy (HAART) relative to that observed in the French general population (FGP) of the same age and sex.
  79. ncbi Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy
    Caroline A Sabin
    Royal Free and University College Medical School, Royal Free NHS Trust, London, UK
    AIDS 18:2145-51. 2004
    ..To investigate the characteristics and clinical, immunological and virological outcomes for individuals presenting for care with low CD4 cell counts...
  80. ncbi Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence
    Jesus Castilla
    Secretaria del Plan Nacional sobre Sida, Ministerio de Sanidad y Consumo, Madrid, Spain
    AIDS 16:1945-51. 2002
    To assess the repercussion of late diagnosis of HIV infection on AIDS incidence in the era of highly active antiretroviral therapy.
  81. ncbi The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era
    Kelly A Gebo
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 40:169-74. 2005
    ..and clinical sequelae of herpes zoster have been studied in the general population and in HIV patients in the era before highly active antiretroviral therapy (HAART), they have yet to be fully understood in the current era of HAART.
  82. pmc Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
    Nancy M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 22:1131-5. 2008
    ..Valproic acid and intensified antiretroviral therapy may deplete resting CD4+ T-cell HIV infection. We tested the ability of valproic acid to deplete resting CD4+ T-cell infection in patients receiving standard antiretroviral therapy...
  83. ncbi Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis
    Hla Hla Thein
    University Health Network, Division of Clinical Decision Making and Healthcare Research, Toronto, Canada
    AIDS 22:1979-91. 2008
    ..in individuals coinfected with HIV and hepatitis C virus (HCV), to examine the effect of covariates on these rates, and to investigate the effect of HIV on HCV-related cirrhosis in the era of highly active antiretroviral therapy (HAART).
  84. ncbi Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children
    Salvador Resino
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 43:243-52. 2006
    ..when combined therapy was administered; CP4 (1997-1998), when </=50% of children were receiving highly active antiretroviral therapy (HAART); and CP5 (1999-2003), when >/=60% of children were receiving HAART.Results...
  85. ncbi Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda
    Fatu Forna
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 44:456-62. 2007
    ..We evaluated clinical toxicity in HIV-infected persons receiving antiretroviral therapy (ART) in Uganda...
  86. ncbi Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy
    Samuel A Shelburne
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Medicine (Baltimore) 81:213-27. 2002
  87. ncbi Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients
    Michael Alan Horberg
    HIV Research, Kaiser Permanente, Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 47:384-90. 2008
    To determine the impact of depression on highly active antiretroviral therapy (HAART) adherence and clinical measures and investigate if selective serotonin reuptake inhibitors (SSRIs) improve these measures.
  88. ncbi Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study
    Ineke G Stolte
    Cluster of Infectious Diseases, HIV and STI Research, Municipal Health Service, Amsterdam, The Netherlands
    AIDS 18:303-9. 2004
    To investigate longitudinally the association between highly active antiretroviral therapy (HAART)-related beliefs and the change from protected to unprotected anal intercourse with casual partners on an individual level.
  89. ncbi CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
    Gilbert R Kaufmann
    Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Arch Intern Med 163:2187-95. 2003
    b>Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART.
  90. ncbi Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data
    Camelia Protopopescu
    INSERM, U912 SE4S, 13006 Marseille, France
    J Antimicrob Chemother 64:599-606. 2009
    The aim of this study was to identify factors associated with non-adherence over a 10 year follow-up of the APROCO-COPILOTE cohort during the maintenance phase of highly active antiretroviral therapy (HAART).
  91. ncbi Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection
    A Ammassari
    Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, Roma, Italy
    J Acquir Immune Defic Syndr 28:445-9. 2001
    To identify variables predictive of nonadherence to highly active antiretroviral therapy (HAART) and to assess whether self-reported symptoms or medication side effects are related to adherence.
  92. pmc r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans
    Aoife M Brennan
    Division of Endocrinology, Diabetes, and Metabolism, Harvard Medical School, Beth Israel Deaconess Medical Center, E St 816, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Eur J Endocrinol 160:173-6. 2009
    ..r-metHuLeptin and IGF1 administration result in reduced central adipose tissue in subjects with highly active antiretroviral therapy-induced metabolic syndrome (HAART-MS) but whether the effects of leptin are mediated through ..
  93. ncbi Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 17:1907-15. 2003
    To determine the extent to which HIV-infected patients, including those with advanced immunodeficiency, can reverse peripheral CD4 T-cell depletion while maintaining long-term viral suppression on highly active antiretroviral therapy.
  94. ncbi CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater
    Luuk Gras
    HIV Monitoring Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 45:183-92. 2007
    CD4 cell count changes in therapy-naive patients were investigated during 7 years of highly active antiretroviral therapy (HAART) in an observational cohort.
  95. pmc Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection
    Vikram S Gill
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Clin Infect Dis 50:98-105. 2010
    ....
  96. ncbi Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection
    Kit N Simpson
    Pharmacy and Clinical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA
    HIV Clin Trials 5:294-304. 2004
    ..nelfinavir (NFV), both coadministered with stavudine and lamivudine, as the first HAART regimen in treating HIV patients, based on the results from the published clinical trial M98-863...
  97. ncbi Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic
    Thomas P Giordano
    Sections of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Texas 77009, USA
    J Acquir Immune Defic Syndr 32:399-405. 2003
    Ethnic minority, female, and drug-using patients may be less likely to receive highly active antiretroviral therapy (HAART), despite its proven benefits...
  98. ncbi Updated research nosology for HIV-associated neurocognitive disorders
    A Antinori
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Instituto di Ricovero e Cura a Carattere Scientifico IRCCS, Rome, Italy
    Neurology 69:1789-99. 2007
    ..An algorithm is proposed to assist in standardized diagnostic classification of HAND...
  99. ncbi Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults
    Jean B Nachega
    Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 43:78-84. 2006
    It is unclear how adherence to highly active antiretroviral therapy (HAART) may best be monitored in large HIV programs in sub-Saharan Africa where it is being scaled up...
  100. ncbi Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease
    E L Murphy
    Department of Laboratory Medicine, University of California, San Francisco, Box 0884, San Francisco, CA 94143 0884, USA
    Ann Intern Med 135:17-26. 2001
    ..Mortality and morbidity related to AIDS have decreased among HIV-infected patients taking highly active anti-retroviral therapy (HAART), but previous studies may have been confounded by other changes in treatment...

Research Grants70

  1. Regulation of Astrocyte TIMP-1 in HIV-Associated Dementia
    JEREL ADAM FIELDS; Fiscal Year: 2011
    ..progress to develop HAD in developed worlds such as the United States, despite the availability of highly active antiretroviral therapy. Our studies will provide a better understanding of the specific mechanistic contributions of ..
  2. The Role of Alcohol in HIV Therapy Hepatotoxicity
    Craig J McClain; Fiscal Year: 2012
    ..Since the introduction of highly active antiretroviral therapy (HAART) in 1996, the life expectancy of patients with HIV has increased significantly...
  3. A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
    John K Buolamwini; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Although the introduction of highly active antiretroviral therapy (HAART) targeting the human immunodeficiency virus (HIV) revolutionized acquired immunodeficiency disease (AIDS) therapy, nucleoside ..
  4. Drug Transport at the Blood-Testis Barrier
    Nathan J Cherrington; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Since its introduction in 1996, highly active antiretroviral therapy (HAART) has been credited with a marked and sustained reduction in AIDS-related death and disease in the United States...
  5. HIV and CD16+ monocytes as cellular reservoir &HIV/pulmonary hypertension
    Sharilyn Almodovar; Fiscal Year: 2013
    ..In addition, pulmonary complications are still prevalent despite the unquestioned success of Highly Active Antiretroviral Therapy (HAART)...
  6. Development of Transdermal Films for the the Delivery of HIV Therapeutics
    Anthony Sang Won Ham; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Highly active antiretroviral therapy (HAART) has been successfully utilized in HIV-infected individuals to significantly reduce disease progression and improve the prognosis of infected individuals...
  7. Control of HIV drug resistance in older patients
    Alonso Heredia; Fiscal Year: 2010
    b>Highly active antiretroviral therapy (HAART) has dramatically increased life expectancy in HIV infection and by 2015 more than half of HIV patients in the U.S. will be older than 50...
  8. Manganese Enhanced Multi-MRI for Murine HIV-1 Associated Neurocognitive Disorders
    Yutong Liu; Fiscal Year: 2013
    ..The cumulative incidence of HIV-1 associated dementia in the Western world is 25-38% with highly active antiretroviral therapy (HAART) and the prevalence is around 37%. Milder forms affect an additional 30-40% of patients...
  9. Astrocyte senescence and HIV-associated neurocognitive disorders
    ELIZABETH PATRICIA CROWE; Fiscal Year: 2013
    ..Despite the use of highly active antiretroviral therapy (HAART), the central nervous system (CNS) is vulnerable to HIV infection and the incidence ..
  10. Role of Oxidative Stress and Inflammation in HIV Cardiovascular Risk
    Cecilia M Shikuma; Fiscal Year: 2012
    ..provided by applicant): HIV-infected patients now live longer because of the availability of highly active antiretroviral therapy (HAART)...
  11. Small Animal Model of HIV Neuropathogenesis in the HAART Era
    Pietro P Sanna; Fiscal Year: 2012
    ..neurocognitive disorders (HAND) continue to affect people with HIV despite the advent of highly active antiretroviral therapy (HAART)...
  12. Mechanisms of mitochondrial fission/fusion dysregulation during HIV-1-associated
    JEREL ADAM FIELDS; Fiscal Year: 2013
    ..Despite 30 years of research and the advent of highly active antiretroviral therapy (HAART), HAND persist...
  13. Cancer Care among Medicare HIV patients
    Sumedha Chhatre; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Background: In the post highly active antiretroviral therapy (HAART) period, large numbers of people living with HIV/AIDS are aging...
  14. Neuronal survival, HIV-1 and Astrocyte TIMP-1
    Anuja Ghorpade; Fiscal Year: 2013
    ..progress to develop HAD in developed worlds such as the United States, despite the availability of highly active antiretroviral therapy. Reactive astrogliosis, recruitment to and proliferation of astrocytes at the site of injury, is ..
  15. HAART optimism, drug use and risky sexual behavior among MSM in British Columbia.
    Robert Stephen Hogg; Fiscal Year: 2013
    ..a recently initiated population-level biomedical intervention- expanded universal and free of cost highly active antiretroviral therapy (HAART)-on HIV risk behaviors among a high-risk population, men who have sex with men (MSM), in ..
  16. Pneumocystis jirovecii Targeted Antiopportunistic Agents
    Aleem Gangjee; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Despite the availability of highly active antiretroviral therapy (HAART or ART), opportunistic infections (OIs) remain the leading cause of considerable morbidity and mortality in HIV infected persons ..
  17. The Role of HIV-1 Evolution in Neuroadaptation
    TERESA EVERING; Fiscal Year: 2013
    ..defined as anatomical or privileged cellular sites in which viral replication may continue despite highly active antiretroviral therapy (HAART). The central nervous system (CNS) is an important sanctuary site for HIV-1...
  18. Rates and determinants of decreased bone health among HIV-infected patients
    Roger Bedimo; Fiscal Year: 2013
    ..by applicant): With the improved survival of HIV-infected patients since the introduction of Highly Active Antiretroviral Therapy (HAART), low bone mass and osteoporotic fractures seem to be emerging as important chronic problems ..
  19. HIV-1 Inhibition using Tat Peptide Derivatives
    Fatah Kashanchi; Fiscal Year: 2013
    ..With the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, survival following HIV diagnosis has risen dramatically and HIV infection ..
  20. PERIPHERAL NEUROPATHY IN LENTIVIRUS INFECTIONS: EARLY VIRAL AND HOST DETERMINANTS
    Christopher Power; Fiscal Year: 2010
    ..distal sensory polyneuropathy (DSP), which can be exacerbated by concurrent therapies, especially highly active antiretroviral therapy (HAART)...
  21. Markers of HIV Brain Disease under HAART: Validation in a Mouse Model
    David J Volsky; Fiscal Year: 2012
    ..at restoring immune function and often cognitive function in demented HIV-1-infected persons, highly active antiretroviral therapy has limited effects upon milder CNS disease that is increasingly prevalent...
  22. CNS Delivery of Activated Antiviral Drugs with Reduced Neurotoxicity (Nano-NRTIs)
    Serguei V Vinogradov; Fiscal Year: 2013
    ..Serious HIV-associated neuropathology and the neurological side effects of Highly Active Antiretroviral Therapy (HAART) have been recently identified as the major hazards of chronic AIDS treatment...
  23. NeuroAIDS Therapy in the EcoHIV Mouse Model
    DAVID VOLSKY; Fiscal Year: 2009
    b>Highly active antiretroviral therapy (HAART) for HIV-1 infection effectively reduces systemic virus burden and improves immune function in most compliant patients...
  24. Platelet Activating Factor, Synaptic Failure &NeuroAIDS
    Harris A Gelbard; Fiscal Year: 2013
    ..b>Highly active antiretroviral therapy (HAART), even with dramatic reduction of viral load, may reverse some symptoms of HAND (often on a ..
  25. Designing HIV Protease Inhibitors with Lower Dosing Requirements and Lower Toxici
    Mitchell W Mutz; Fiscal Year: 2013
    ..HIV protease inhibitors are a mainstay of highly active antiretroviral therapy (HAART) with annual sales of over $2.5 billion...
  26. Development of Novel AIDS Gene Therapy Strategies in the Macaque SHIV Model
    Hans Peter Kiem; Fiscal Year: 2012
    ..b>Highly active antiretroviral therapy (HAART) has reduced the morbidity and mortality associated with HIV infection, but the emergence of ..
  27. Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction
    Rick B Meeker; Fiscal Year: 2013
    ..While disease severity has been reduced with the advent of highly active antiretroviral therapy, CNS disease persists and is expected to exert an increasingly heavy toll as patients with HIV live ..
  28. Cannabinoid modulation of microglial response to the HIV protein Tat
    Guy A Cabral; Fiscal Year: 2013
    ....
  29. IDO Regulation in the SIV Model of HIV CNS Disease
    M Christine Zink; Fiscal Year: 2013
    DESCRIPTION (provided by applicant):While highly active antiretroviral therapy (HAART) has dramatically improved the quality of life for HIV-infected individuals, there has been an increase in the prevalence of HIV-associated ..
  30. Impacts of universal access to HIV/AIDS care among HIV+ injection drug users
    Evan Wood; Fiscal Year: 2013
    ..individuals, resulting in lower rates of infection in populations with higher levels of coverage of highly active antiretroviral therapy (HAART...
  31. Role of B-cells and CNS antibodies in modulating chronic microglial activation
    James R Lokensgard; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Effective highly active antiretroviral therapy (HAART) reduces HIV RNA levels in cerebrospinal fluid (CSF), as well as in plasma, and has produced profound improvements in health and longevity...
  32. Cardioprotective Efficacy ofMg-Supplementation during HAART Therapy
    IVAN TONG MAK; Fiscal Year: 2011
    ..provided by applicant): Tenofovir (TFV), efavirenz (EFV) and ritonavir (RTV) are the first line highly active antiretroviral therapy (HAART) agents used in most treatment of HIV patients...
  33. Dopamine alters CNS migration of uninfected and HIV infected leukocytes to SDF-1
    JOAN WEINBERGER BERMAN; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Although highly active antiretroviral therapy (HAART) has proven effective in treating individuals infected with human immunodeficiency virus 1 (HIV), neuropsychological abnormalities are still major ..
  34. Impact of Malnutrition on HIV Treatment Failure in Resource-Limited Settings
    Amita Gupta; Fiscal Year: 2012
    b>Highly active antiretroviral therapy (HAART) has reduced morbidity and mortality in HIV-infected persons worldwide. However, early treatment failure (i.e...
  35. Challenging and Expanding Paradigms of Aging with HIV
    KERI NICOLE ALTHOFF; Fiscal Year: 2013
    ..increased risk of comorbidities in HIV-infected individuals? 3) What is the impact of the timing of highly active antiretroviral therapy (HAART) initiation on the risk of comorbidities? These questions will be asked by investigating the ..
  36. A Novel CNS-Penetrable Antiretroviral
    Ned C Sacktor; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Since the introduction of highly active antiretroviral therapy (HAART) in the mid-1990's for treatment of human immunodeficiency virus type 1 (HIV-1) infection, overall incidence rates of ..
  37. Interaction of Alcohol and HAART in HIV/AIDS and HIV/AIDS and HCV Coinfection
    Elinore F McCance Katz; Fiscal Year: 2011
    ..We hypothesize that concomitant use of alcohol and currently utilized highly active antiretroviral therapy (HAART) will be associated with significant drug interactions including alteration of alcohol and ..
  38. Virus/host interaction in HIV neuropathogenesis
    LISA JANE HENDERSON; Fiscal Year: 2012
    ..Although the introduction of highly active antiretroviral therapy (HAART) has significantly decreased the incidences of HAD, the prevalence of neurocognitive/motor ..
  39. Impact of maternal HAART on HIV-infected breastfeeding infants: Malawi
    Susan H Eshleman; Fiscal Year: 2013
    ..However, use of highly active antiretroviral therapy (HAART) in breastfeeding women may induce ARV resistance in some HIV-infected infants, either ..
  40. Role of Host miRNAs in Persistent HIV Macrophage Infection
    Judy Lieberman; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Treatment with highly active antiretroviral therapy suppresses, but does not eradicate, HIV-infected cells...
  41. Genetics of susceptibility to candidiasis
    Scott Filler; Fiscal Year: 2009
    ..is a significant problem in patients with HIV/AIDS, especially those who are not receiving highly active antiretroviral therapy. Also, hematogenously disseminated candidiasis is common in hospitalized patients and still causes ..
  42. HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium
    Steven S Gross; Fiscal Year: 2013
    ..Despite the increased survival of individuals with HIV-1 (HIV) infection resulting from the use of highly active antiretroviral therapy (HAART), individuals infected with HIV have an increased risk for the development of chronic ..
  43. HAART to Prevent HIV Transmission to Infants In Botswana
    Roger L Shapiro; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Highly active antiretroviral therapy (HAART) is rapidly becoming available in the developing world, but the safety and efficacy of different HAART regimens for preventing mother-to-child HIV ..
  44. Solid Organ Transplantation in HIV: Multi-Site Study
    Peter G Stock; Fiscal Year: 2010
    ..Prior to the advent of highly active antiretroviral therapy (HAART), such patients were often not considered as transplant candidates based on poor prognosis...
  45. Role of p53 family in neuropathogenesis in AIDS
    Bassel E Sawaya; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Despite the use of Highly active antiretroviral therapy (HAART), neuronal cell death remains a problem that is frequently found in the brains of HIV-1-infected patients...
  46. Neuroprotective and Antiviral Effects of BMD-101 and BMD-104 in HIV Infection
    Christopher G Conrad; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): The introduction and implementation of highly active antiretroviral therapy (HAART) in AIDS patients diminished HIV viral load and led to an increase in life expectancy, but HIV infection can still ..
  47. Effects of Acitretin on the activation of latent HIV
    Peilin Li; Fiscal Year: 2013
    DESCRIPTION: More than 33 million people in the world live with HIV. Treatment with highly active antiretroviral therapy (HAART) has been successful, but therapy is not curative...
  48. Identification and eradication of HIV tissue reservoirs in a relevant animal mode
    Binhua Ling; Fiscal Year: 2013
    ..provided by applicant): Although HIV-infected long-term nonprogressors (LTNP) and those on highly active antiretroviral therapy (HAART) have undetectable virus in blood;it is known that virus persists in yet unknown tissue ..
  49. CAUSES OF AND ASSOCIATIONS WITH DEATH DURING LONG TERM HAART IN AFRICA
    Christopher J Hoffmann; Fiscal Year: 2013
    ..Recent wide-spread introduction of highly active antiretroviral therapy (HAART) to treat HIV in Africa has reduced mortality;however, mortality rates remain higher than in ..
  50. The Effectiveness of Screening HIV-Infected Women for Anal Cancer Precursors
    Elizabeth Chiao; Fiscal Year: 2013
    ..of developing anal carcinoma compared with the general population despite the widespread use of highly active antiretroviral therapy (HAART)...
  51. Sex, Aging and Antiretroviral Pharmacology
    Kristine B Patterson; Fiscal Year: 2012
    ..HIV RNA dynamics in blood plasma and genital tract secretions before and after the initiation of highly active antiretroviral therapy. Research Methods: First- dose, steady-state and longitudinal pharmacokinetics of the most commonly ..
  52. The regulation of cannabinoid receptors in microglial cells during HIV infection
    CATALIN FILIPEANU; Fiscal Year: 2012
    ..are over one million people in the United States infected with HIV, and due to the introduction of highly active antiretroviral therapy, HIV infection has become a chronic disease frequently co-existing with chronic use of prescribed, ..
  53. Health Promotion for Positives: A Randomized Trial with HIV Positive Black Men
    JOHN BARTON JEMMOTT; Fiscal Year: 2013
    ..increased risk is heightened by HIV infection, but also its treatment with certain agents used in highly active antiretroviral therapy (HAART) combinations...
  54. Determinants of HIV Dynamics and Variation
    JOSE ORLANDO MALDONADO-ORTIZ; Fiscal Year: 2013
    ..b>Highly active antiretroviral therapy (HAART) is currently the best treatment for HIV infection...
  55. HIV and Global Drug Therapies: Peripheral Neuropathy Complications and Mechanisms
    Cecilia M Shikuma; Fiscal Year: 2012
    Rates of HIV-associated sensory neuropathies (HIV-SN) remain high despite the introduction of highly active antiretroviral therapy (HAART)...
  56. Novel antivirals targeting the RNase H activity of HIV reverse transcriptase
    Zhengqiang Wang; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Highly active antiretroviral therapy (HAART) drugs primarily target three of the four HIV enzymes: reverse transcriptase (RT) DNA polymerase, protease, and integrase...
  57. Lopinavir/ritonavir + zidovudine to prevent perinatal HIV in Thailand
    Marc J Lallemant; Fiscal Year: 2013
    ..In industrialized countries, more complex regimens using highly active antiretroviral therapy (HAART) combinations during pregnancy also achieve very low transmission rates while avoiding the ..
  58. Mechanisms of HIV Protease Inhibitor-Induced Lipid Dysregulation in Adipocytes
    BETH S ZHA; Fiscal Year: 2012
    The development of highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality in HIV-infected patients, yet the regimen also often results in chronic metabolic diseases...
  59. HIV Latency, Epigenetics, and Therapeutics
    David M Margolis; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Highly active antiretroviral therapy (ART) has lead to a significant decrease in the morbidity and mortality of HIV-infected individuals,..
  60. Breastmilk Transmission of HIV: Virology, Pharmacokinetics, and Adherence in BAN
    Susan A Fiscus; Fiscal Year: 2010
    ..applicant): In the Breastfeeding, Antiretrovirals and Nutrition Study (BAN), 28 weeks of maternal highly active antiretroviral therapy (HAART) started at delivery decreased transmission by 52% and 28 weeks of extended infant NVP ..
  61. Mitochondrial Toxicity of Antiviral Nucleosides
    Edward E McKee; Fiscal Year: 2010
    Antiretroviral nucleoside analogs used in highly active antiretroviral therapy (HAART) are associated with a variety of tissue toxicities associated with mitochondrial DNA depletion, suggesting a block in mt-DNA replication...
  62. Early-Stage Chronic Kidney Disease in HIV-infected Individuals
    Gregory M Lucas; Fiscal Year: 2013
    ..Cross-sectional studies in the era of highly active antiretroviral therapy (HAART) indicate that the prevalence of albuminuria is 3- to 5-times higher in HIV-infected ..
  63. Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn
    George Cox; Fiscal Year: 2009
    ..redistribution syndrome (HARS), a form of lipodystrophy, is a common problem in HIV patients on highly active antiretroviral therapy and occurs as a side-effect of their anti-viral drug therapies...
  64. Cellular Efflux and Metabolism of Protease Inhibitors
    Ashim Mitra; Fiscal Year: 2004
    ..Moreover the existence of "sanctuary" sites of HIV-1 may potentially endanger the efficacy of highly active antiretroviral therapy (HAART)...
  65. Nucleoside Transporters In HAART Mitochondrial Toxicity
    John Buolamwini; Fiscal Year: 2006
    The introduction of highly active antiretroviral therapy (HAART) has been successful in prolonging the lives of HIV/AIDS patients...
  66. Glycogen synthase kinase-3beta: a setpoint for dopamine dysfunction in neuroAIDS
    Seth Perry; Fiscal Year: 2009
    ..is increasing in prevalence, despite success reducing viral load in HIV-infected individuals with highly active antiretroviral therapy (HAART)...
  67. ART PHARMACOKINETICS IN SEVERELY MALNOURISHED HIV-INFECTED CHILDREN
    Ericka Hayes; Fiscal Year: 2009
    ..objective of this project is to understand how severe malnutrition affects the pharmacokinetics of highly active antiretroviral therapy (HAART) as well as antioxidant capacity and mitochondrial integrity in HIV infected children ..
  68. Development of immune assays for HPV-32
    Michael Hagensee; Fiscal Year: 2006
    ..The understanding of immune response to oral HPV infection may help to predict HPV disease progression as well as elucidate therapeutic and preventive strategies for HPV-related disease. ..
  69. CLINICAL GENE THERAPY PROGRAM FOR THE TREATMENT OF AIDS
    Rafael Amado; Fiscal Year: 2002
    ..The advent of highly active antiretroviral therapy has been associated with a decline in the incidence of opportunistic infections and prolonged ..
  70. Antiretroviral Therapy of AIDS-Related Kaposi's Sarcoma in Africa
    Jeffrey Martin; Fiscal Year: 2009
    ..In HIV-infected patients with KS in resource-rich areas, use of highly active antiretroviral therapy (HAART) often causes regression of KS even in the absence of conventional chemotherapy...